A Long-term Extension Study of PCI-32765 (Ibrutinib)
A phase 3 trial of Ibrutinib in mantle cell lymphoma and follicular lymphoma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Long-term Extension Study of PCI-32765 (Ibrutinib) is a phase 3 interventional study registered as NCT01804686 by Janssen Research & Development, LLC, with 700 participants planned, started 2013-09-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- PersonYuqin Song
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialGene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialA Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
- TermLugano classification / Ann Arbor staging
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Shares Ibrutinib, Diffuse large B-cell lymphoma.
- CollectionLymphoma Research Foundation (LRF)
Shares Mantle cell lymphoma, Follicular lymphoma, Diffuse large B-cell lymphoma.